CN115044515B - 抗宠物腹泻复合益生菌及其应用 - Google Patents
抗宠物腹泻复合益生菌及其应用 Download PDFInfo
- Publication number
- CN115044515B CN115044515B CN202210812730.6A CN202210812730A CN115044515B CN 115044515 B CN115044515 B CN 115044515B CN 202210812730 A CN202210812730 A CN 202210812730A CN 115044515 B CN115044515 B CN 115044515B
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- probiotics
- probiotic
- zjuids
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 103
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 103
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 55
- 239000002131 composite material Substances 0.000 title claims abstract description 30
- 230000000529 probiotic effect Effects 0.000 claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 13
- 241000186660 Lactobacillus Species 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 13
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 50
- 241001465754 Metazoa Species 0.000 claims description 28
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 12
- 230000001142 anti-diarrhea Effects 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 241000282326 Felis catus Species 0.000 claims description 5
- 235000012054 meals Nutrition 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000186712 Lactobacillus animalis Species 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 34
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 210000003608 fece Anatomy 0.000 abstract description 13
- 239000003833 bile salt Substances 0.000 abstract description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 12
- 239000002253 acid Substances 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 239000004310 lactic acid Substances 0.000 abstract description 6
- 235000014655 lactic acid Nutrition 0.000 abstract description 6
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 108010000231 Choloylglycine hydrolase Proteins 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000002354 daily effect Effects 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 235000021050 feed intake Nutrition 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000015784 hyperosmotic salinity response Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 241001156739 Actinobacteria <phylum> Species 0.000 description 3
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 241000192700 Cyanobacteria Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 229960000740 enrofloxacin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000372691 Candidatus Saccharibacteria Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001261005 Verrucomicrobia Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000003170 nutritional factors Nutrition 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001134446 Niveas Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/117—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Sustainable Development (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供抗宠物腹泻复合益生菌及其应用。所述复合益生菌由植物乳杆菌ZY08、屎肠球菌ZJUIDS‑R1、动物联合乳杆菌ZJUIDS‑R2按照等比例组合。本发明从健康宠物粪便中分离获得的益生菌并进行组合。该益生菌组合物具有较强的胆盐水解酶活力,在耐酸耐胆盐方面比其他乳酸菌有明显的优势,适合肠胃环境并具有增殖能力。该益生菌组合物具有良好的抗菌活性,能抑制肠内有害的病原菌。所述复合益生菌可在制备预防宠物腹泻产品中的应用。本发明中的复合益生菌可广泛用于开发各种宠物预防腹泻相关益生功能产品。
Description
技术领域
本发明属于动物微生物技术领域,涉及抗宠物腹泻复合益生菌及其应用。
背景技术
在宠物动物饲养过程中,因其脆弱的消化系统常发生胃肠道疾病。腹泻的发生通常与肠道微生物的区系变化有关,约80%的患病兔会出现腹泻这一症状。出现该症状的原因可以分为环境因素、营养因素和病原因素,在宠物的饲养过程中,占比最大的原因是营养因素,例如饲喂高蛋白、高纤维或含高碳水化合物饲料,以及饲料发霉、饲料中随意添加抗生素等都会引起动物发生腹泻。
目前,市面上用于预防宠物兔及其他宠物腹泻的疫苗较少,进行治疗时主要采用药物调控和生物调控。随着禁止使用抗生素的进程,腹泻等疾病防治开始寻找新的出路,益生菌、寡聚糖和酶制剂等具有巨大的应用前景,其中益生菌相关的研究最多。
2001年,FAO和WHO联合专家咨询会将益生菌定义为“活的微生物,当摄入足够的数量时,会给宿主带来未指明的健康益处”。机体摄入的外来有益细菌,通过与胃肠道免疫系统和微生物菌群相互作用,对宿主健康产生积极的影响。当受到外界刺激后,肠道内菌群失调,有害菌大量繁殖,有益菌难以对抗,自身稳态被打破,此时补充益生菌事半功倍,能在较短时间内发挥作用。益生菌在动物机体内通过免疫调节、增加肠道屏障功能、维持肠道菌群平衡、调节营养物质等作用机制影响宿主健康,能有效降低幼龄动物的发病率和死亡率、提高成年动物生产性能、改善肉质、提高饲料转化率等。益生菌作为一种天然高效环保的添加剂,是目前为止最有效的抗生素替代品。
发明内容
本发明的目的是提供抗宠物腹泻复合益生菌,所述复合益生菌由植物乳杆菌ZY08、屎肠球菌ZJUIDS-R1、动物联合乳杆菌ZJUIDS-R2按照等比例组合。所述植物乳杆菌ZY08,屎肠球菌ZJUIDS-R1,动物联合乳杆菌ZJUIDS-R2均已保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏地址为北京市朝阳区北辰西路1号院3号,保藏号分别为:植物乳杆菌ZY08为CGMCC NO.14847,保藏日期:2017年11月1日;屎肠球菌ZJUIDS-R1为CGMCCNO.24376,保藏日期:2022年1月24日;动物联合乳杆菌ZJUIDS-R2为CGMCCNO.24560,保藏日期:2022年3月21日。
本发明从健康宠物的粪便中筛选出两株益生菌,分别为屎肠球菌ZJUIDS-R1(Enterococcus Faecium),和动物联合乳杆菌ZJUIDS-R2(Ligilactobacillus animalis),从健康的婴儿粪便中分离到一株植物乳杆菌ZY08(Lactobacillus plantarum)通过细菌形态学、生理学、培养特性和16S rDNA测序等对该菌进行了鉴定。
本发明的另一个目的是提供所述复合益生菌在制备预防宠物腹泻产品中的应用。本发明涉及的宠物主要有:犬、猫、兔、豚鼠、龙猫、仓鼠等。本发明主要是针对动物的细菌性腹泻,且偏向多种致病菌混合感染导致的腹泻。导致动物腹泻的病原微生物主要又分为细菌、真菌、病毒、寄生虫等。引起动物腹泻的细菌常见于大肠杆菌、沙门氏菌、魏氏梭菌、巴氏杆菌、产气荚膜梭菌等,其中以大肠杆菌为病因的腹泻占首位,单一病原菌可以引起动物腹泻,也可以与其他病原菌混合感染发病,在生产和生活中混合感染引起的腹泻占比最大。
所述产品为具有抗腹泻功能的药品、宠物饲料或宠物零食等。
本发明所述的具有预防腹泻功能的药品包括具有抗腹泻功能的益生菌复合活菌制剂或益生菌复合活菌菌液,该活菌制剂或菌液中活菌数为1.0×1010~5.0×1010CFU/g。
本发明所述的具有抗动物腹泻功能的饲料由所述抗宠物腹泻的益生菌组合混合发酵制备。所述饲料优选为具有预防腹泻功能的草粉(例如为提摩西草草粉)混合物。
本发明所提供的益生菌组合在动物试验中腹泻预防率达到90%(n=10)。其具有以下能力:(1)具有较强的胆盐水解酶活力;(2)能耐受酸和胆盐,并且具有一定的增殖能力;具有抗菌活性;具有较高的凝集率和疏水性。即,能耐受胃肠道环境、无抗生素耐性、能抑制肠内有害的病原菌,与肠上皮细胞具有较高的亲和力,能阻碍致病菌在肠道的定植的和感染。
本发明从宠物粪便中分离获得的益生菌组合具有预防宠物腹泻功能。该复合益生菌产品具有较强的胆盐水解酶活力,适合肠胃环境并具有增殖能力。无抗生素耐性,具有抗菌活性。本发明中的动物联合乳杆菌可广泛用于开发预防动物腹泻相关益生功能产品。
附图说明
图1为复合腹泻粪便形状图。注:腹泻初期可观察到兔肛门周围存在粪便内容物,粪便形状不规则,出现一头带尖或者两头都带尖,且粪便普遍变小。严重者排出稀软粪便,颗粒不成形或带有胶冻样物质。
图2为复合益生菌肠道形态图。注:腹泻兔肠道鼓气,肠道积液,结肠粪便变小且大小不均,粪便有少量黏液包裹,多段肠管空虚,偶见肠套叠现象,肠壁变薄呈透明状,蚓突可见大量白色突起,触摸有明显颗粒感。
图3为不同组动物的肠道切片,其中N为对照组;A为抗生素组;T为益生菌组。
具体实施方式
下面结合附图和具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此。
实施例1抗腹泻复合益生菌产品的制备
1.1菌株来源
本发明所使用的菌株均从花鸟市场、健康宠物粪便样品中分离获得。粪便样品共采集53份,其中所有采样对象在被采样前的至少一个月时间内未出现腹泻等胃肠道疾病。其中植物乳杆菌ZY08,屎肠球菌ZJUIDS-R1,动物联合乳杆菌ZJUIDS-R2已于均保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号分别为:植物乳杆菌ZY08为CGMCCNO.14847;屎肠球菌ZJUIDS-R1为CGMCC NO.24376;动物联合乳杆菌ZJUIDS-R2为CGMCCNO.24560。
1.2菌株的培养
将植物乳杆菌ZY08,屎肠球菌ZJUIDS-R1,动物联合乳杆菌ZJUIDS-R2菌株从-80℃冰箱取出,放于室温溶解,分别挑取少量甘油管菌液于LB培养基上活化,24h后挑取LB培养基上的指示菌株单菌落再划线传代3次。将最后一次活化的单菌落接种于LB液体培养基中,37℃静置培养24小时后取出,4℃离心机8000rmp,离心15min,弃去上清液保存下层菌体沉淀并重悬,使活菌数达到分别达到109CFU/mL。
1.3复合菌液的制备
将植物乳杆菌ZY08,屎肠球菌ZJUIDS-R1,动物联合乳杆菌ZJUIDS-R2的菌液(109CFU/mL)按照1:1:1的比例混合菌均匀,用于后续测定。
实施例2复合益生菌产品抗腹泻能力的确认
1.复合益生菌菌液的制备
参考实施例1的益生菌及组合进行菌液产品的制备。
2.体外抗菌能力的测定
2.1指示菌株培养
将四种指示菌株(大肠杆菌ATCC 25922、鼠伤寒沙门氏菌ATCC 13311、金黄色葡萄球菌CMCC 26003、单核细胞增生李斯特菌CMCC5400)从-80℃冰箱取出,放于室温溶解,分别挑取少量甘油管菌液于LB培养基上活化,24h后挑取LB培养基上的指示菌株单菌落再划线传代3次。将最后一次活化的单菌落接种于LB液体培养基中,37℃静置培养24小时后取出,4℃离心机8000rmp,离心15min,弃去上清液保存下层菌体沉淀并重悬,使活菌数达到108CFU/mL。
2.2琼脂扩散法
采用国际通用琼脂扩散法测量乳酸菌代谢产物的抑菌活性。
使用光口锥形瓶配置LB固体培养基,待培养基灭菌后置于55℃水浴保温,等温度降下来后放于超净台中,将指示菌菌液按照1%的量接入锥形瓶中,摇晃至混合菌液,将指示菌悬液与LB固体培养基混合好后倒入已经放置牛津杯的平皿中制成15mL/皿的LB平板。待LB平板凝固后,用无菌镊子轻轻拔掉牛津杯。每孔定量加入200μL,以恩诺沙星溶液为阳性对照,接入乳酸菌悬液和发酵上清液,将接好液体的平板放于37℃,培养24h。培养结束后,用游标卡尺测量抑菌圈直径并记录。
表1.复合益生菌对病原菌抑制能力的结果
表1的结果显示,复合益生菌对常见的致病菌都有较好的抗菌效果,其中对大肠杆菌和鼠伤寒沙门氏菌的抗菌效果最好。
实施例3复合益生菌的耐酸性、耐胆盐性和疏水性的确认
复合益生菌酸耐受性的测定
参考实施例一制备复合益生菌,以10%(v/v)的量将活菌数为108CFU/mL的复合益生菌菌悬液接种于pH为1.5的MRS液体配培养基中(液体培养基pH使用1M的NaOH与HCl调节),分别在试验进行的0h、3h采样。为保证数值准确,使用倾注法进行活菌数的计数。取100μL的复合益生菌菌悬液注入15mL的55℃左右的MRS固体培养基内,冷却至平皿内培养基定型,37℃静置培养培养24h后计数,并基于所得数值分别计算复合益生菌3h后的酸耐受率,酸耐受计算公式如下:
酸耐受率(%)=A3/A0×100
A3=经酸处理3h的乳酸菌株的活菌数;A0=乳酸菌株初始溶液的活菌数
复合益生菌胆盐耐受性的测定
参考实施例1制备复合益生菌,以10%(v/v)的量将活菌数为108CFU/mL的复合益生菌菌悬液接种于0.3%牛胆盐(v/v)的MRS液体配培养基中,分别在试验进行的0h、3h采样。为保证数值准确,使用倾注法进行活菌数的计数。取100μL的乳酸菌菌悬液注入15mL的55℃左右的MRS固体培养基内,冷却至平皿内培养基定型,37℃静置培养培养24h后计数,并基于所得数值分别计算乳酸菌3h后的胆盐耐受率,胆盐耐受计算公式如下:
胆盐耐受率(%)=T3/T0×100
T3=胆盐处理3h的益生菌的活菌数;T0=益生菌初始溶液的活菌数。
乳酸菌疏水性的测试
取2mL复合益生菌菌悬液和2mL二甲苯彻底混合,37℃水浴充分震荡5min,并在2h后测量水相的吸光值,益生菌疏水性计算公式如下:
疏水作用力(%)=(A0-A2)/A0×100
A0=益生菌菌株0h的吸光值;A2=益生菌菌株处理后2h的吸光值。
表2.复合益生菌对酸、胆盐耐受性和疏水性结果
菌株 | 酸耐受率(%) | 胆盐耐受率(%) | 疏水性(%) |
复合益生菌 | 89.9 | 2.36 | 45.7 |
益生菌必须能够耐受胃肠道中胃酸和胆汁等一系列不良环境而活着才能发挥其益生作用。本发明提供的复合益生菌产品在pH 1.5的条件下能够生长增殖,其能顺利通过胃中的酸性环境到达小肠。同时,复合益生菌能耐受胆盐,在肠道内存活,进而能有效地预防腹泻的作用。复合益生菌产品疏水率为45.7%,说明益生菌在肠道可以较好的聚集在一起,抵抗减少损失。
实施例5抗腹泻复合益生菌对宠物兔腹泻的预防作用
1、试验动物和试验设计
试验动物选取30只体重接近、健康程度一致的30日龄新西兰大白兔,随机分为3组,每组雌雄各半,分别记为N(空白对照)组、A(抗生素饲喂)组、T(复合益生菌饲喂)组。试验周期28天,前三周,N组、A组和T组分别饲喂无菌生理盐水、抗生素(恩诺沙星)、复合益生菌,最后一周饲喂常见肠道致病菌(大肠杆菌、鼠伤寒沙门氏菌、单核细胞增生李斯特菌和金黄色葡萄球菌),初步探索复合益生菌对细菌性腹泻的预防作用。
2、基础日粮与饲养管理
本实验断奶幼兔采用笼养方式,每天饲喂2次,根据幼兔日龄调整饲喂量,每晚将未吃完的饲料进行称量,自由饮水,每天打扫兔舍的卫生,保证幼兔良好的生活环境。其中A组为基础日粮+生理盐水;B组为基础日粮+拜有利(3mg/Kg/d);T组为基础日粮+复合益生菌(1mL/kg/d,1×108cfu/mL)。其他按照日常管理进行。
基础日粮的原料有:玉米、麸皮、豆粕、苜蓿草粉、碳酸钙、氯化钠、鱼粉、复合维生素、复合微量元素等。基础日粮营养成分见表4。
表4基础日粮营养成分表
营养成分 | 单位 | 含量 | 判定合格界限 |
粗蛋白 | % | 14.12 | 12.4-17.0 |
粗灰分 | % | 10.4 | ≤12.5 |
水分 | % | 10.1 | ≤13.9 |
钙 | % | 1.14 | 0.45-1.4 |
总磷 | % | 0.76 | ≥0.3 |
黄曲霉毒素B1 | Μg/kg | 未检出(<1.0) | ≤26 |
注:表中营养成分均为实测值。
3、测定指标
在试验周期内按时记录兔的采食量、体重,试验结束时,每只断奶幼兔进行耳源静脉采血,取1mL放入肝素钠采血管,取1.5mL放于无菌空白EP管。随后,对断奶幼兔进行剖检取样,取内脏器官肝脏、脾脏和肾脏;每段肠管取样三份;取样前,快速测量兔蚓突长度。试验结束后从兔生长性能、血液生化、血液炎症、血液抗体浓度等指标分析饲喂抗生素和复合益生菌对宠物兔的影响。
(1)腹泻发生率
试验后期,断奶幼兔饲喂肠道致病菌后,观察并记录断奶幼兔腹泻发生情况,拍照记录腹泻幼兔粪便形态,计算各组断奶幼兔腹泻发生率。图1为腹泻兔子的粪便形状图。
由表5可以看出,N组的腹泻率在所有分组中最高,且明显高于A组、T组的腹泻率,而A组、T组腹泻率基本无差异。即给断奶幼兔饲喂抗生素和ZJUIDS-R1均能降低幼兔的腹泻率。
表5益生菌对断奶幼兔腹泻率的影响
腹泻发生率(100%) | |
N组 | 50.0 |
A组 | 10* |
T1组 | 10* |
*代表差异显著;
(2)生长性能
通过计算每组断奶幼兔的采食量、日增重和饲料转化率初步评估益生菌对断奶幼兔生长性能的影响。
从表6结果可以看出,N组日采食量与A组存在明显差异,N组日采食量最高,其次是T组、A组;在3个分组中,N组平均日增重最多,其次是A组和T组,但3组之前无显著性差异;计算饲料转化率后发现,A组饲料转化率最高,其次是N组、T组。即在试验期间,N组日采食量最高,同样日增重也最高,但A组料重比最低,益生菌对断奶幼兔生长性能无显著性影响。
表6益生菌对断奶幼兔生长性能的影响
测定指标 | 日采食量(g) | 日增重(g) | 饲料转化率 |
N组 | 139.0±10.6a | 36.1±3.3a | 3.9±0.26a |
A组 | 114.3±6.9b | 31.9±5.6a | 3.7±0.74a |
T组 | 127.0±8.3ab | 33.3±4.9a | 4.7±0.59b |
注:同一列未共用同一上表字母的均值间存在显著差异(P<0.05)。
(3)血液生化指标
试验结束时,每只断奶幼兔采集血液,使用爱德士全自动生化仪测定血浆葡萄糖(GLU)、血液肌酐(CREA)、血液尿素氮(BUN)、总蛋白(TP)、白蛋白(ALB)、球蛋白(GLOB)、白球比(ALB/GLOB)、丙氨酸氨基转移酶(ALT)、碱性磷酸酶(ALKP)等生化指标。
由表7可知,不同处理下N组、A组、T组这3组GLU、BUN、TP、ALB、GLOB、ALT、ALKP等生化指标均无显著性差异(P>0.05)。但与N组对比分析发现,N、A两组血液内的GLU、BUN、TP、ALB降低,CREA增高。
表7益生菌对断奶幼兔血液生化的影响的影响
检测项目 | 单位 | N组 | A组 | T组 |
葡萄糖GLU | mg/dL | 108.20±28.03 | 95.67±26.90 | 87.33±31.49 |
肌酐CREA | mg/dL | 0.94±0.09b | 1.23±0.29a | 1.14±0.15ab |
尿素氮BUN | mg/dL | 22.4±7.16 | 20.00±10.14 | 19.77±8.59 |
尿素氮/肌酐BUN/CREA | 17.80±4.44a | 10.35±4.89b | 11.22±3.33b | |
总蛋白TP | g/dL | 34.94±37.51 | 26.28±30.39 | 27.85±25.44 |
白蛋白ALB | g/dL | 18.62±19.63 | 14.78±17.22 | 15.67±11.69 |
球蛋白GLOB | g/dL | 16.48±18.55 | 11.65±13.46 | 13.22±10.18 |
白球比ALB/GLOB | 1.28±0.22a | 1.25±0.08a | 1.02±0.27b | |
谷丙转氨酶ALT | U/L | 61.4±30.53 | 68.67±15.59 | 59.77±10.49 |
碱性磷酸酶ALKP | U/L | 119.80±45.32 | 119.17±29.53 | 109.65±29.89 |
注:同一列未共用同一上表字母的均值间存在显著差异(P<0.05)。
(4)血液炎症指标
试验结束时,每只断奶幼兔进行耳源静脉采血,取1.5mL放于无菌空白EP管内,空白管里的血液,3000r离心10min,分离出上层的血清,通过酶联免疫吸附实验(ELISA)检测血清里的C反应蛋白(CRP)指标。
由表8可知,T组CRP显著低于N、A两组(P<0.05),A组CRP相对N组出现下降,但两组差异不显著(P>0.05)。总体而言,A组、T组都呈下降趋势,即断奶幼兔饲喂抗生素与复合益生菌均能降低幼兔全身炎症指标,且复合益生菌降低全身炎症的效果明显好于抗生素。
表8益生菌对断奶幼兔血清C反应蛋白的影响
CRP(mg/L) | |
N组 | 8.51±0.73a |
A组 | 8.15±0.73a |
T组 | 6.31±0.58b |
注:同一列未共用同一上表字母的均值间存在显著差异(P<0.05)。
(5)血液抗体指标
使用上述分离得到的血清,通过酶联免疫吸附实验(ELISA)检测血清抗体浓度(IgG、IgM、IgA)。由表9可知,T组的三种抗体水平都显著高于N组和A组(P<0.05)。即断奶幼兔补充复合益生菌能显著提高血液内IgA、IgG和IgM抗体水平。
表9生菌对断奶幼兔血清抗体浓度的影响
注:同一列未共用同一上表字母的均值间存在显著差异(P<0.05)。
(6)益生菌对断奶幼兔盲肠菌群的影响
由表10可知,各分组的coverage指数都等于0.99,表明各组之间样本中序列被测出的概率一样高,同样表明本次测序结果可以代表样本中微生物的真实情况。
通过对比不同分组间的四个指数发现,A组OTU、chaos、Shannon指数最高,T组Simpson指数最低。三组之间α多样性指数无显著性差异。
表10益生菌对断奶幼兔肠道菌群α多样性的影响
注:同一列未共用同一上表字母的均值间存在显著差异(P<0.05)。
断奶幼兔盲肠内菌群在门水平的变化如表11所示。在所有分组中厚壁菌门(Firmicutes)丰度最高,其次是拟杆菌门(Bacteroidetes)、放线菌门(Actinobacteria)和变形菌门(Proteobacteria)。饲喂益生菌后,T组中的Bacteroidetes、Bacteroidetes、Actinobacteria增加,与N组相比,疣微菌门(Verrucomicrobia)、单糖菌门(Saccharibacteria)、蓝藻菌门(Cyanobacteria)等数量增加,表明饲喂益生菌后肠道菌群有所改善。
表11断奶幼兔盲肠菌群在门水平的变化
N组 | A组 | T组 | |
Firmicutes | 40811 | 36755 | 40062 |
Bacteroidetes | 7003 | 7918 | 7894 |
Actinobacteria | 902 | 1767 | 1698 |
Proteobacteria | 472 | 1463 | 898 |
Verrucomicrobia | 252 | 409 | 439 |
Saccharibacteria | 55 | 140 | 161 |
Tenericutes | 125 | 45 | 122 |
Cyanobacteria | 38 | 89 | 137 |
(7)十二指肠组织切片
图2为兔子腹部剖开图,不同组的肠道组织切片见图3,图中可以看下益生菌组在组织切片的效果接近与抗生素组,显著优于空白组,表明益生菌处理可以缓解对组织的损伤。
绒毛高度(VH)越高,与肠道内容物的接触面积越大;隐窝深度(CD)越浅表明细胞的成熟度越好,分泌功能和吸收功能也越好;绒毛高度与隐窝深度比值(V/C值)与动物的生长速度呈正相关。由表12可以看出,与N组相比,益生菌组均显著提高了断奶幼兔十二指肠VH和V/C,降低了CD(P<0.05),其作用程度与抗生素组无显著性差异。上述结果表明益生菌对断奶幼兔十二指肠发育存在有益作用。
表12益生菌对断奶幼兔十二指肠的影响
VH(mm) | CD(mm) | V/C | |
N组 | 950.44±75.12b | 290.34±19.32a | 3.27±0.05b |
A组 | 1381.20±209.60a | 252.95±22.08b | 5.44±0.45a |
T组 | 1399.24±218.77a | 201.09±18.56b | 5.99±0.36a |
实施例6利用抗腹泻复合益生菌制备预防腹泻菌粉
1.复合益生菌菌泥的制备
挑取单菌落接种于50mL MRS液体培养基中,放置37℃培养箱中培养24h。再次按5%的接种量于250mL MRS液体培养基中活化,放置37℃培养箱中培养24h。最后将活化好的单菌以5%接种量于10L发酵罐中进行高密度厌氧培养,于37℃、pH 6.8的条件下培养24h。之后在8000r/min、4℃条件下离心15min,弃去上清液,收集菌体沉淀,用无菌磷酸盐缓冲液(pH 7.0)漂洗菌体2次,可制的单菌菌泥。
按照1:1:1的比例将3个单菌的菌泥混合均匀后用于后续制备
2.保护剂的制备
冻干保护剂含有15%的脱脂乳粉,5%的海藻糖,3%的谷氨酸钠,1%的甘油,0.5%的半胱氨酸盐酸盐。水作为溶剂。于110℃灭菌备用。
3.复合益生菌菌粉的制备
将上述制备的复合菌菌体沉淀按1:5的比例与保护剂溶液充分混匀。于-40℃条件下预冻5h,使其均匀冻结在容器内壁上,然后进行真空冷冻干燥,干燥18~20h后,即可得到复合益生菌菌粉。用生理盐水复水后,洗涤两次,测得复合益生菌菌粉中活菌数为1.0×1011~5×1011CFU/g。
实施例7利用抗腹泻复合益生菌制备预防宠物腹泻草粉
复合益生菌预防宠物腹泻提摩西草粉的步骤如下:
(1)原料准备:提摩西草收割后,保证清洁,无腐败变质,将其切断至1~2cm,再打磨成粉;
(2)将实施例6所制备的复合益生菌菌粉按0.02‰接种量接种到原料中,混合均匀;
(3)储藏条件:避光保存,温度为15~25℃,时间为2年。
实施例8利用抗腹泻复合益生菌制备预防兔腹泻滴剂
预防兔腹泻滴剂,由以下质量比的原料制备而成:低聚半乳糖1%、油酸1%、植物油10%、卵磷脂1%、维生素2%、ZJUIDS-R1菌粉、纯净水35%、丙三醇50%。
将实施例6所制备的动物联合乳杆菌ZJUIDS-R2菌粉按1%的比例添加进去,混合后活菌数达到1.0×108CFU/ml以上。产品密封、避光低温保存,保质期为1年。
实施例9利用抗腹泻复合益生菌制备防腹泻宠物奶粉
宠物专用防腹泻奶粉,包括以下百分比的原料:羊奶粉65-70%、混合植物油25%,复合益生菌(活菌数>108CFU/g),矿物质2%,预混剂(维生素、微量元素等)2%、葡萄糖和麦芽糊精3%。上述防腹泻奶粉可增强机体免疫力,从根源上解决断奶幼兔肠道功能不适、肠道致病菌感染等引起的腹泻问题。
实施例10利用抗腹泻复合益生菌制备犬猫胃肠道处方膏
主要包括以下百分比的原料:麦芽糖15%、茯苓10%、陈皮15%、山楂5%、白术(炒)5%、鸡内金5%、预混剂(维生素和微量元素等)5%、纯净水35%,复合益生菌(活菌数>108CFU/mL),制备成牙膏状。本产品可以促进肠道免疫,增加机体抵抗力,适用于犬猫疫苗或驱虫不完善、消化不良、食欲不振等。使用方法:体重小于5kg:每天两次,每次3mL;体重5-15kg:每天两次,每次4mL;体重大于15kg:每天两次,每次5mL。本产品可直接饲喂,可拌在粮食内混合饲喂,也可涂抹在爱宠鼻子上让其舔食。
最后,还需要注意的是,以上列举的仅是本发明的若干个具体实施例。显然,本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
Claims (6)
1.一种抗宠物腹泻复合益生菌,其特征在于,所述复合益生菌由植物乳杆菌ZY08(Lactobacillus plantarum)、屎肠球菌ZJUIDS-R1(Enterococcus Faecium)、动物联合乳杆菌ZJUIDS-R2(Ligilactobacillus animalis)按照等比例组合,所述植物乳杆菌ZY08保藏号为CGMCC NO. 14847;屎肠球菌ZJUIDS-R1保藏号为CGMCC NO. 24376,动物联合乳杆菌ZJUIDS-R2保藏号为 CGMCC NO. 24560。
2.权利要求1所述的复合益生菌在制备预防宠物腹泻产品中的应用,其特征在于,所述产品为有抗腹泻功能的药品、宠物饲料或宠物零食。
3.根据权利要求2所述的应用,其特征在于,所述药品是有抗腹泻功能的活菌制剂或菌液,该活菌制剂或菌液中复合益生菌的活菌数为1.0×1010~5.0×1010 CFU/g。
4.根据权利要求2所述的应用,其特征在于,所述的宠物饲料由复合益生菌单独或与其他菌株混合发酵制备。
5.根据权利要求4所述的应用,其特征在于,所述的宠物饲料为有预防腹泻功能的草粉混合物。
6.根据权利要求2所述的应用,其特征在于,所述宠物为犬、猫、兔、豚鼠、龙猫、仓鼠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812730.6A CN115044515B (zh) | 2022-07-11 | 2022-07-11 | 抗宠物腹泻复合益生菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210812730.6A CN115044515B (zh) | 2022-07-11 | 2022-07-11 | 抗宠物腹泻复合益生菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115044515A CN115044515A (zh) | 2022-09-13 |
CN115044515B true CN115044515B (zh) | 2024-04-16 |
Family
ID=83165348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210812730.6A Active CN115044515B (zh) | 2022-07-11 | 2022-07-11 | 抗宠物腹泻复合益生菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115044515B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108102959A (zh) * | 2017-12-23 | 2018-06-01 | 浙江大学 | 人源性降胆固醇植物乳杆菌zy08及其应用 |
CN110623984A (zh) * | 2019-10-22 | 2019-12-31 | 江苏恒丰强生物技术有限公司 | 一种治疗腹泻的四联活菌制剂及其应用 |
CN111803529A (zh) * | 2020-07-21 | 2020-10-23 | 石河子大学 | 一种预防犊牛腹泻的复合微生态制剂 |
CN113061547A (zh) * | 2020-12-30 | 2021-07-02 | 内蒙古和美科盛生物技术有限公司 | 一种用于降低仔猪腹泻发病率的复合益生菌制剂及其制备方法和应用 |
WO2022000080A1 (en) * | 2020-06-29 | 2022-01-06 | Canbiocin Inc. | Compositions and related methods for supporting companion animals with gastrointestinal disorders |
WO2022043223A1 (en) * | 2020-08-28 | 2022-03-03 | Chr. Hansen A/S | Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate |
CN114540239A (zh) * | 2022-03-10 | 2022-05-27 | 浙江大学 | 一株兔源性预防宠物腹泻屎肠球菌zjuids-r1及其应用 |
-
2022
- 2022-07-11 CN CN202210812730.6A patent/CN115044515B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108102959A (zh) * | 2017-12-23 | 2018-06-01 | 浙江大学 | 人源性降胆固醇植物乳杆菌zy08及其应用 |
CN110623984A (zh) * | 2019-10-22 | 2019-12-31 | 江苏恒丰强生物技术有限公司 | 一种治疗腹泻的四联活菌制剂及其应用 |
WO2022000080A1 (en) * | 2020-06-29 | 2022-01-06 | Canbiocin Inc. | Compositions and related methods for supporting companion animals with gastrointestinal disorders |
CN111803529A (zh) * | 2020-07-21 | 2020-10-23 | 石河子大学 | 一种预防犊牛腹泻的复合微生态制剂 |
WO2022043223A1 (en) * | 2020-08-28 | 2022-03-03 | Chr. Hansen A/S | Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate |
CN113061547A (zh) * | 2020-12-30 | 2021-07-02 | 内蒙古和美科盛生物技术有限公司 | 一种用于降低仔猪腹泻发病率的复合益生菌制剂及其制备方法和应用 |
CN114540239A (zh) * | 2022-03-10 | 2022-05-27 | 浙江大学 | 一株兔源性预防宠物腹泻屎肠球菌zjuids-r1及其应用 |
Non-Patent Citations (1)
Title |
---|
双歧杆菌、乳杆菌和芽孢杆菌产细菌素和多糖研究进展;于钊瑞;食品工业科技;第42卷(第24期);第2.1节 * |
Also Published As
Publication number | Publication date |
---|---|
CN115044515A (zh) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104195075B (zh) | 一种屎肠球菌ef08及包含它的饲料添加物和饲料 | |
CN102480995B (zh) | 用于动物饲料的组分及其用途 | |
JP2023075359A (ja) | 微生物細胞、それを生成する方法、およびその使用 | |
JP2015205896A (ja) | 動物の健康を向上するためにバチルス・ズブチリス株を使用する方法 | |
CN114540239B (zh) | 一株兔源性预防宠物腹泻屎肠球菌zjuids-r1及其应用 | |
CN112011481A (zh) | 一株防治畜禽细菌性腹泻的罗伊氏乳杆菌及其应用 | |
CN104673726A (zh) | 一种猪源嗜酸乳杆菌冻干制剂及其应用 | |
CN108402320A (zh) | 一种复合益生菌制剂及其在仔猪饲料中的应用 | |
CN102373162A (zh) | 唾液乳酸杆菌(Lactobacillus salivarius)M6及含有该唾液乳酸杆菌M6的抑菌组合物 | |
CN113061547A (zh) | 一种用于降低仔猪腹泻发病率的复合益生菌制剂及其制备方法和应用 | |
CN109486732B (zh) | 一种长双歧杆菌及其应用 | |
JP4199685B2 (ja) | 新規な乳酸菌 | |
CN114788548A (zh) | 一种中药渣发酵饲料添加剂及其制备方法和应用 | |
CN115024382B (zh) | 一株抗动物腹泻动物联合乳杆菌zjuids-r2及其应用 | |
CN115044515B (zh) | 抗宠物腹泻复合益生菌及其应用 | |
CN114908009B (zh) | 一株口粘液乳杆菌pr63及其应用 | |
GB2484126A (en) | Foodstuff fermented with lactic acid producing bacteria | |
CN113475633B (zh) | 应用于断奶仔猪生长中的发酵中草药、方法、饲料及应用 | |
CN106282276A (zh) | 一种芽孢杆菌抗菌肽的制备方法和应用 | |
CN115927070A (zh) | 一株芽孢杆菌及其应用 | |
CN114032200A (zh) | 一种养殖动物的枯草芽孢杆菌饲料添加剂的制备方法 | |
GB2485476A (en) | Lactic acid producing bacteria for use in fermented feed | |
JP2009044971A (ja) | 反芻家畜に対するプロバイオティック効果をサイレージ調製用乳酸菌に付加する新規酵母菌およびその利用 | |
RU2378000C2 (ru) | Способ получения лечебно-профилактической добавки | |
CN113862196A (zh) | 一株枯草芽孢杆菌sd-kc-001及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |